^
Association details:
| Biomarker: | BACH2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | R-CHOP (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma
Excerpt:
All patients were treated with rituximab-containing chemotherapy...In cases with high BACH2-expression, 3-year OS rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). The 3-year PFS was also shorter than that with low expression, although it was not significant (62.5% vs 80.3%, P = 0.0681).
DOI:
10.1111/cas.12361
